Cardiac markers into the new millennium

Annals of Clinical Biochemistry

Volumn 37, Issue 2, 2000, Pages 109-113

  Collinson, Paul O ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; TROPONIN;

DISEASE MARKER; HEART DISEASE; HEART MUSCLE INJURY; HUMAN; NOTE; PRIORITY JOURNAL;

EID: 0033996061     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563001898989     Document Type: Note

References (31)

1. Zijstra F, Hoorntje JCA, de Boer M-J, Reiffers S, Miedma K, Ottervanger JP, et al. Long term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-9
2. Faxon DP, Heger JW. Primary angioplasty - enduring the test of time. N Engl J Med 1999; 341: 1464-5
3. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction. Lancet 1999; 359: 716-22
4. Fragmin and Fast revascularisation during Instability in Coronary artery disease (FRISC II) Investigators. Long term low molecular mass heparin in unstable coronary artery disease: FRISC II prospective multicentre study. Lancet 1999; 354: 701-7
5. Fragmin and Fast revascularisation during Instability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-15
6. Goy J-J. Contemporary approach to management of unstable angina. Lancet 1999; 354: 694-5
7. White HD. Future of reperfusion therapy for acute myocardial infarction. Lancet 1999; 354; 695-7
8. Hamm CW, Heeschen C, Goldman B, Vahanian A, Adgey J, Miguel CM, et al. Benefit of acbciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999; 340: 1623-9
9. Heescheen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD for the PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999; 354: 1757-62
10. Wu AHB, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in Coronary Artery Diseases. Clin Chem 1999; 45: 1104-21
11. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AHB. Recommendations on use of biochemical markers of cardiac damage in acute coronary syndromes. Scand J Clin Lab Invest 1999 ; 59(suppl 230): 103-12
12. Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Ann Int Med 1986; 105: 221-33
13. Werner M, Brooks SH, Mohrbacher RJ, Wasserman AG. Diagnostic performance of enzymes in the discrimination of myocardial infarction. Clin Chem 1982; 28: 1297-302.
14. Leung FY, Galbraith LV, Jablonsky G, Henderson AR. Re-evaluation of the diagnostic utility of serum total creatine kinase and creatine kinase-2 in myocardial infarction. Clin Chem 1989; 35: 1435-40
15. Mair J, Artner-Dworzak E, Dienstl A, Lechleitner P, Morass B, Smidt J, et al. Early detection of acute myocardial infarction by measurement of mass concentration of creatine kinase-MB. Am J Cardiol 1991; 68: 1545-50
16. Collinson PO, Rosalki SB, Kuwana T, Garret H, Ramhamadamy E, Greenwood TW, et al. Early diagnosis of acute myocardial infarction by CK-MB mass measurements. Ann Clin Biochem 1992; 29: 43-47
17. Ross SM, Fraser CG. Biological variation of cardiac markers: analytical and clinical considerations. Ann Clin Biochem 1998; 35: 80-4
18. Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998; 81: 1405-10
19. Campbell RW, Wallentin L, Verheugt FW, et al. Management strategies for a better outcome in unstable coronary artery disease. Clinical Cardiology 1998; 21: 314-22.
20. Collinson PO. Cost economics of new cardiac markers - CK-MB and cardiac troponins. In: Kaski CJ, Holt D, eds. Myocardial Damage: Early detection by Novel biochemical Markers. The Netherlands: Kluwer Academic Publishers B.V, 1998: 173-87
21. Gibler WB, Runyon JP, Levy RC, Sayre MR, Kacirh R, Hattemer CR, et al. A rapid diagnostic and treatment centre for patients with chest pain in the emergency department. Ann Emerg Med 1995; 25:1-8
22. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996; 94:1291-7
23. Collinson PO, Premachandram S, Hashemi K. Prospective audit of the incidence of prognostically significant myocardial damage in patients discharged from the Emergency Department. BMJ 2000; 320, in press
24. Collinson PO, Stubbs PJ. 4 hour "rule-in" diagnosis of acute myocardial infarction for early risk stratification by creatine kinase increment (CK change). Ann Clin Biochem 1996; 33: 308-13
25. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337: 1648-53
26. Point of care testing or central laboratory testing: an evaluation. Collinson PO, John CM, Cramp DRG, Carson ER, Morgan SH, Canepa-Anson R. Health Technol Assess 2000; 4, in press
27. Collinson PO. The need for a point of care testing: an evidence-based appraisal. Scand J Clin Lab Invest (Suppl) 1999; 230: 67-73
28. Heeschen C. Goldmann BU. Langenbrink L. Matschuck G. Hamm CW. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 1999; 45:1789-96
29. Hedges JR. Cardiac enzyme availability and hospital length of stay. Clin Chem 1997; 43: 249-50
30. Lindahl B, Venge P, Wallentin L, Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43-8
31. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. BMJ 1996; 313: 262-4